Literature DB >> 25845841

Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study.

O Ahlehoff1,2,3, P R Hansen3, G H Gislason3, M Frydland1, L E Bryld4, H Elming2, G B E Jemec4.   

Abstract

BACKGROUND: Psoriasis is a chronic inflammatory disease and is associated with cardiovascular events. Little is known about subclinical myocardial dysfunction and potential changes in myocardial function during anti-inflammatory treatment in these patients. We prospectively studied left ventricular function in patients with severe psoriasis who initiated biologic therapy.
METHODS: Between November 1 2013 and May 31 2014 the study subjects underwent physical, laboratory and comprehensive echocardiographic examination at baseline and after 3 months of treatment. Pearson correlation coefficients and Student's t-test were applied to assess changes in diastolic function (defined as the E/e' ratio) and global longitudinal strain (GLS).
RESULTS: Eighteen patients with severe psoriasis treated with biologic therapy with a mean follow-up of 85.6 ± 18.2 days were included. The patients had a baseline psoriasis area and severity index (PASI) of 12.0 ± 4.1 and normal left ventricular ejection fraction [(LVEF) 56.3 ± 3.8%], diastolic dysfunction (E/e' 8.1 ± 2.1) and GLS (-16.8 ± 2.1%). At follow-up, an improvement (baseline vs. follow-up) of PASI (12.0 ± 4.1 vs. 2.7 ± 3.1, P < 0.001), E/e' (8.1 ± 2.1 vs. 6.7 ± 1.9, P ≤ 0.001) and GLS (-16.8 ± 2.1 vs. -18.3 ± 2.3%, P < 0.001) were recorded. No changes were demonstrated in LVEF (56.3 ± 3.8 vs. 56.8 ± 3.3%, P = 0.31), body mass index (30.9 ± 5.7 vs. 31.0 ± 5.8 kg/m(2) , P = 0.90), mean arterial blood pressure (103.1 ± 8.5 vs. 103.7 ± 10.8 mmHg, P = 0.74). Likewise, no changes were seen in total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, estimated glomerular filtration rate and glycosylated haemoglobin.
CONCLUSION: In patients with severe psoriasis treatment with biologic therapy was associated with improved PASI and amelioration of myocardial dysfunction.
© 2015 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25845841     DOI: 10.1111/jdv.13152

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  9 in total

Review 1.  Comorbidity in Adult Psoriasis: Considerations for the Clinician.

Authors:  Christine Daugaard; Lars Iversen; Kasper Fjellhaugen Hjuler
Journal:  Psoriasis (Auckl)       Date:  2022-06-10

Review 2.  Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?

Authors:  Gloria Orlando; Barbara Molon; Antonella Viola; Mauro Alaibac; Roberta Angioni; Stefano Piaserico
Journal:  Front Immunol       Date:  2022-05-24       Impact factor: 8.786

Review 3.  Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.

Authors:  Milena Aksentijevich; Sundus S Lateef; Paula Anzenberg; Amit K Dey; Nehal N Mehta
Journal:  Trends Cardiovasc Med       Date:  2019-11-20       Impact factor: 6.677

Review 4.  New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.

Authors:  Di Yan; Andrew Blauvelt; Amit K Dey; Rachel S Golpanian; Samuel T Hwang; Nehal N Mehta; Bridget Myers; Zhen-Rui Shi; Gil Yosipovitch; Stacie Bell; Wilson Liao
Journal:  J Invest Dermatol       Date:  2021-04-19       Impact factor: 7.590

Review 5.  Psoriasis-associated vascular disease: the role of HDL.

Authors:  Maria Joao Paiva-Lopes; José Delgado Alves
Journal:  J Biomed Sci       Date:  2017-09-14       Impact factor: 8.410

Review 6.  Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.

Authors:  Giuseppina Caiazzo; Gabriella Fabbrocini; Roberta Di Caprio; Annunziata Raimondo; Emanuele Scala; Nicola Balato; Anna Balato
Journal:  Front Immunol       Date:  2018-08-13       Impact factor: 7.561

Review 7.  Management of psoriasis as a systemic disease: what is the evidence?

Authors:  N J Korman
Journal:  Br J Dermatol       Date:  2019-10-15       Impact factor: 9.302

8.  Biomarkers of inflammation and left ventricular remodelling in psoriasis patients treated with infliximab.

Authors:  Helga Midtbø; Ester Kringeland; Eva Gerdts; Per Magne Ueland; Klaus Meyer; Anja Linde; Arve Ulvik; Roland Jonsson; Kåre Steinar Tveit
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

Review 9.  The Association Between Psoriasis and Cardiovascular Diseases.

Authors:  Ahmed Zwain; Mohanad Aldiwani; Hussein Taqi
Journal:  Eur Cardiol       Date:  2021-05-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.